How Much BAC Water for BPC-157 (5 mg, 10 mg)?

Key takeaways

• There is no legitimate answer to how much bacteriostatic water goes into a 5 mg or 10 mg vial of BPC-157, and we do not publish one. No US pharmacy may compound or dispense it in October 2026, so no pharmacy label exists, and no human dose has been established.
• Water never sets the dose; it only sets how many syringe units carry one. The questions that matter are what is in the vial and what dose, if any, is safe and useful, and no mixing volume answers either.
• Seller charts most often say 2 mL for either vial and 250 to 500 mcg per injection. Decoded, their 250 mcg is 10 units from a 5 mg vial and 5 units from a 10 mg vial. No study supports those numbers, and 5-unit doses are where 10-fold errors happen.
• The only published human doses were procedures at one clinic: 10 mg injected once into the bladder wall, and 10 mg then 20 mg by intravenous infusion in two people. None resembles a daily shot from a home-mixed vial.
• Legal status: off FDA's Category 2 list since April 2026 and recommended 8-6-1 by FDA's advisory committee in July 2026, but no rule has been published, so no pharmacy may make it. It is prohibited in sport under WADA class S0.

There is no correct amount of bacteriostatic water for a 10 mg or 5 mg vial of BPC-157, and we do not give one. A mixing volume means something only for a product with a pharmacy label stating the milligrams, the diluent and the prescribed dose, and BPC-157 has no such product in the United States: it has never been approved anywhere, and as of October 2026 no licensed pharmacy may compound it, as our BPC-157 profile explains. The BAC water calculator states the rule we follow: water volumes and units only for products a pharmacy can legally dispense. What we can do is decode what seller charts claim, show what that arithmetic hides, and explain why the number you are looking for would not make the vial any safer. Our retatrutide page applies the same reasoning to the most searched research peptide of 2026.

Why no honest volume exists

A water volume is the last link in a chain, and for BPC-157 every earlier link is missing.

• No dose. No human study has established a dose, route, frequency or duration. An orthopedic review in 2025 found only three human pilot studies and called the human data extremely limited (McGuire 2025). Those studies used procedures, not daily injections: 10 mg injected once around the inflamed bladder wall during cystoscopy in 12 women (Lee 2024), and 10 mg on one day then 20 mg the next, each infused over an hour, in two adults (Lee 2025). The 250 to 500 mcg on seller charts traces back to rat studies.
• No formulation. A 2026 drug-development review found no approved formulation, no validated dosing regimen and no pharmaceutical-grade formulation, and listed formal excipient-compatibility studies among the missing basics (Mateescu 2026). We found no published study of how long BPC-157 stays intact once dissolved in bacteriostatic water.
• No verified content. The 10 mg is the seller's statement. A 2026 review of unregulated injectable peptides lists contamination, manufacturing impurities and inaccurate dosing among their risks (Moiz 2026), and FDA's reviewers questioned what BPC-157 products even contain: the material on the market varies, with no settled salt or free-base form (HPM 2026).
• No label. Without a pharmacy there is no beyond-use date, no storage instruction, no lot number and no one to call.

What seller charts claim, decoded

These are claims from vendor and forum charts we reviewed in October 2026, decoded so you can see what they say. No study supports any of the doses, and nothing in this section is a recommendation or an instruction.

Most charts tell buyers to add 2 mL of bacteriostatic water to either a 5 mg or a 10 mg vial, others anything from 1 to 5 mL, and they list 250 to 500 mcg per injection once or twice a day. The arithmetic of those claims:

• A 5 mg vial with 2 mL is 2.5 mg/mL, so the charts' 250 mcg is 0.1 mL, or 10 units on a U-100 syringe, the example in our BPC-157 profile.
• A 10 mg vial with 2 mL is 5 mg/mL, so the same 250 mcg is 0.05 mL, or 5 units, and 500 mcg is 10 units.

The arithmetic is internally consistent, and it is the only part of a chart anyone can check. Everything it rests on is not.

What the arithmetic hides

• Five units is the error zone. A 0.05 mL dose is two and a half marks on a 1 mL syringe marked every 2 units. FDA's 2024 alert on compounded semaglutide described patients told to draw 5 units who injected 50 instead (FDA 2024): a 10-fold error, made with a labeled pharmacy product.
• Every dose inherits the label's error. If a vial sold as 10 mg holds 7 mg, every 250 mcg dose by the chart is 175 mcg; if it holds 13 mg, 325 mcg. Nobody selling the vial has to tell you which.
• The vial outlives any safe window. At 250 mcg a 10 mg vial is 40 doses: 40 days of punctures once daily, 20 days twice daily. The convention for an opened multi-dose vial is to discard it 28 days after the first puncture, and that convention assumes a sterile, pharmacy-made product (CDC).
• Bacteriostatic water is not a sterilizer. Its benzyl alcohol slows bacterial growth after repeated punctures. It does not make a contaminated powder sterile, and it does nothing about endotoxin or impurities already in the vial.
• The bundled water is part of the legal case. FDA's 2026 warning letters to online peptide sellers treated reconstitution calculators and bacteriostatic water bundled with vials as evidence that research-labeled products were drugs for people (ArentFox Schiff 2026); the Gram Peptides letter listed the water itself among the products (FDA, Gram Peptides). Those letters concerned GLP-1 drugs, retatrutide, tesamorelin and others rather than BPC-157, but the reasoning applies to any peptide sold with a mixing chart.

Legal and sport status, October 2026

• Never approved, not compoundable. BPC-157 has never been a component of an approved drug, has no USP monograph and is not on FDA's list of bulk substances that 503A pharmacies may use.
• Recommended, not permitted. FDA removed it from Category 2 on April 15, 2026 after its nomination was withdrawn. On July 23, 2026 the Pharmacy Compounding Advisory Committee voted 8 to 6 with one abstention to recommend adding it to the permitted list, over the objection of FDA's own reviewers (HPM 2026), who cited missing human trial data, uncertain identity and composition, and immunogenicity risk (Kelley Drye 2026). FDA must propose and finalize a rule first; none had appeared by October 9, 2026. The legal tracker will record it when one does.
• A prescription does not change it. A clinician can write one, but no licensed pharmacy may fill it, so a service that ships BPC-157 with a prescription is shipping a research vial.
• Prohibited in sport. USADA lists BPC-157 in WADA class S0, non-approved substances, and says a therapeutic use exemption is unlikely (USADA). S0 substances are prohibited at all times, and anti-doping laboratories have had a validated urine test since 2017 (Cox 2017).

If you are already using it

We cannot make a research vial safe, but some signs mean stop and get care the same day: spreading redness, warmth or swelling at the injection site, fever or chills, hives, wheezing, or swelling of the face or throat. Tell the clinician exactly what you injected and bring the vial, because a wellness injection is easy to leave out of a medication history. The BPC-157 side effects page covers what is and is not known about harms.

If the reason you bought it is a tendon, joint or gut problem, the treatments with controlled-trial evidence are available on prescription today; the BPC-157 profile and our BPC-157 for gut health guide set them out next to the rat data. For any peptide a pharmacy can legally dispense, the BAC water calculator and the reconstitution calculator do the arithmetic against a real label.

Bottom line

How much bacteriostatic water to mix with 10 mg or 5 mg of BPC-157 has no honest answer because the questions behind it have none: what is in the vial, what dose a person should take, how long the solution lasts and whether it is sterile. Seller charts answer the easy part, the division, and leave out everything else. In October 2026 BPC-157 is recommended by a committee, opposed by FDA's reviewers, permitted for no pharmacy and banned in sport; a mixing chart does not change any of that.

Frequently asked questions

+−How much BAC water to mix with BPC 157 10mg?

There is no legitimate answer, and we do not give one. No US pharmacy may compound or dispense BPC-157 in October 2026, no human dose has been established, and the 10 mg on a research vial is unverified. Seller charts most often say 2 mL, which would make their 250 mcg dose 5 units; that is a seller's claim with no study behind it, and 5-unit doses are exactly where 10-fold measuring errors happen.

+−How much BAC water for 5 mg BPC-157?

The same answer: no pharmacy label, no established dose, no verified content. Seller charts usually say 2 mL, which makes their 250 mcg dose 10 units. Decoding the claim does not turn it into a dose. No human study used 250 mcg; the only published human doses were 10 mg injected once into the bladder wall and 10 to 20 mg by intravenous infusion, at one clinic.

+−Has the FDA approved BPC-157?

No, and it has never been approved in any country. It is also not legally compoundable: it came off FDA's Category 2 list on April 15, 2026, and FDA's advisory committee voted 8 to 6 with one abstention on July 23, 2026 to recommend it, against the advice of FDA's own reviewers, but FDA has not published a rule. Until it does, no US pharmacy may make it.

+−Can I get a BPC-157 prescription online?

A clinician can write one, but no licensed US pharmacy may fill it in October 2026, because BPC-157 passes none of the tests in federal compounding law. A telehealth service that ships BPC-157 with a prescription attached is shipping a research vial. Ask which pharmacy, in which state, on what legal basis; for BPC-157 there is no good answer.

+−Does BPC-157 show up on a drug test?

On an anti-doping test, yes. A validated urine method detects BPC-157 and a metabolite at 0.1 ng/mL, and WADA lists it in class S0, non-approved substances, which are prohibited at all times; USADA says a therapeutic use exemption is unlikely. Routine workplace drug screens do not look for it.

+−How many units is 1 mL for peptides?

100 units on a standard U-100 insulin syringe, so 10 units is 0.1 mL and 5 units is 0.05 mL. Units measure volume only. How much peptide is in them depends on the concentration of the vial, and for a research vial even the milligrams behind that concentration are unverified.

+−How long is BPC-157 good for after mixing?

Nobody knows. We found no published study of BPC-157's stability once dissolved in bacteriostatic water, and a 2026 drug-development review lists formal excipient-compatibility studies among the basics that do not exist. The 28-day ceiling for opened multi-dose vials applies to sterile, pharmacy-made products; a research vial has no beyond-use date at all.

Sources

1. ReviewMcGuire FP et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025;18:611-9. (2025)
2. StudyLee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med 2024;30(10):12-17. (2024)
3. StudyLee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med 2025;31(5):20-24. (2025)
4. ReviewMateescu DM et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics 2026;18:625. (2026)
5. ReviewMoiz A, O'Keefe EL, O'Keefe JH. Dangers of injectable peptides and other unregulated biohacking drugs. Mo Med 2026;123:337-43. (2026)
6. StudyCox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal 2017;9:1490-8. (2017)
7. NewsPalmer KL, Snow CD, Bass M. PCAC approves four bulk drug substances for the 503A list (BPC-157, KPV, TB-500, MOTS-c). FDA Law Blog, Hyman Phelps & McNamara, July 24, 2026. (2026)
8. NewsKelley Drye. FDA advisory committee recommends several peptides for compounding despite staff opposition: what stakeholders need to know. July 30, 2026. (2026)
9. NewsArentFox Schiff. RUO-ined: five peptide vendors learn that research use only is not a legal strategy (FDA warning letters of August 24, 2026). September 18, 2026. (2026)
10. RegulatoryFDA. Warning letter to Gram Peptides (retatrutide, tirzepatide and bacteriostatic water sold with research-use labels). March 31, 2026. (2026)
11. RegulatoryFDA. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. July 26, 2024. (2024)
12. GuidelineCDC. Injection safety: clinical safety guidance for healthcare providers (single-dose vials, multi-dose vials, 28-day rule). Reviewed March 2024. (2024)
13. SourceUSADA. BPC-157: what athletes should know about the prohibited experimental peptide (S0 non-approved substances; TUE unlikely). Accessed October 10, 2026. (2026)